Real‐world study: Impact of multidisciplinary management of apalutamide‐associated adverse events in prostate cancer
The Prostate · 2024
DOI: 10.1002/pros.24755 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Prostate, 2024. Verfasst von Julián Córdoba Sánchez und 11 weiteren Autor:innen. Beteiligte Einrichtung: Uro-Oncology Unit, Hospital Clínic de, Barcelona, Spain. Hauptthemen laut MEDLINE: Thiohydantoins, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
Objective
To analyse the adverse events (AEs) associated with apalutamide and the impact of a multidisciplinary team (MDT) protocol on its management at a tertiary care hospital in a real‐world setting.
Methods
This was an observational, prospective, cohort study based on real‐world evidence at the Hospital Clínic de Barcelona. Includes patients diagnosed with metastatic hormone‐sensitive prostate cancer (mHSPC) or high‐risk nonmetastatic castration‐resistant prostate cancer (nmCRPC) and who started treatment with apalutamide between May 2019 and March 2023 in a real‐world clinical setting.
Results
Of the 121 patients treated with apalutamide, 52.1% experienced an AE, 19.8% experienced temporarily interruption or a reduction in the dose of apalutamide, and 13.2% discontinued treatment due to AEs. Without MDT protocol (49 patients), 24.5% of patients had to temporarily interrupt or reduce the dose of apalutamide due to AEs, with a median time from the start of treatment of 10.1 months, and 24.5% discontinued apalutamide due to AEs, with a median time from the start of treatment of 3.1 months. Meanwhile, whit MDT protocol (72 patients), 16.7% of patients had to temporarily interrupt or reduce the dose of apalutamide due to AEs, with a median time from the start of treatment of 1.6 months, and 5.6% discontinued apalutamide due to AEs, with a median time from the start of treatment of 4 months. The risk reduction associated with treatment discontinuation was statistically significant ( p‐ value = 0.003).
Conclusions
This study highlights the importance of MDT management of AEs associated with apalutamide to reduce treatment discontinuation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Uro-Oncology Unit, Hospital Clínic de, Barcelona, Spain.
- Pharmacy Department, Hospital Clínic de, Barcelona, Spain.
- Dermatology Department, Hospital Clínic de, Barcelona, Spain.
- Clinical Pharmacology Department, Hospital Clínic de, Barcelona, Spain.
- Medical Oncology Department, Hospital Clínic de, Barcelona, Spain.
- Radiotherapy Oncology Department, Hospital Clínic de, Barcelona, Spain.
ORCID-Profile: Cristina Carrera, Antoni Vilaseca
Zitieren
APA
Córdoba Sánchez, J., Monge-Escartín, I., Gil, J., Carrera, C., Sáez-Peñataro, J., Ferrer, L., Aversa, C., Mellado, B., Mases, J., Ribal, M. J., Alcaraz, A., & Vilaseca, A. (2024). Real‐world study: Impact of multidisciplinary management of apalutamide‐associated adverse events in prostate cancer. The Prostate. https://doi.org/10.1002/pros.24755
Vancouver
Córdoba Sánchez J, Monge-Escartín I, Gil J, Carrera C, Sáez-Peñataro J, Ferrer L, et al. Real‐world study: Impact of multidisciplinary management of apalutamide‐associated adverse events in prostate cancer. The Prostate. 2024. doi:10.1002/pros.24755
BibTeX
@article{CrdobaSnchez2024,
author = {Córdoba Sánchez, Julián and Monge-Escartín, Inés and Gil, Javier and Carrera, Cristina and Sáez-Peñataro, Joaquín and Ferrer, Laura and Aversa, Caterina and Mellado, Begoña and Mases, Joel and Ribal, Maria Jose and Alcaraz, Antonio and Vilaseca, Antoni},
title = {Real‐world study: Impact of multidisciplinary management of apalutamide‐associated adverse events in prostate cancer},
journal = {The Prostate},
year = {2024},
doi = {10.1002/pros.24755}
}
EUVIMED